Provided by Tiger Trade Technology Pte. Ltd.

CSTONE PHARMA-B

6.080
-0.085-1.38%
Volume:22.34M
Turnover:137.17M
Market Cap:9.70B
PE:-19.32
High:6.360
Open:6.165
Low:5.970
Close:6.165
52wk High:12.900
52wk Low:4.010
Shares:1.60B
HK Float Shares:1.60B
Volume Ratio:1.14
T/O Rate:1.40%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.315
ROE:-52.14%
ROA:-14.44%
PB:6.43
PE(LYR):-19.32
PS:19.53

Loading ...

Portfolio Alert: HK-Listed CSTONE PHARMA-B Surges 6% on Stock Connect Inclusion and Global Trial Milestones

Stock News
·
Sep 08

CStone Pharmaceuticals Joins Stock Connect Southbound Trading

MT Newswires Live
·
Sep 07

CStone Pharmaceuticals Included in Southbound Stock Connect, Targeting Greater Liquidity and Global Trial Progress

Bulletin Express
·
Sep 07

CStone Pharma Shares Added to Southbound Stock Connect Eligible List

Reuters
·
Sep 07

CStone Pharmaceuticals Posts Marginal Share Increase in August 2026 Monthly Return

Bulletin Express
·
Sep 04

Is CStone Pharmaceuticals (SEHK:2616) Fully Valued On Interim Results And CS2009 Progress?

Simply Wall St.
·
Sep 03

CSTONE PHARMA-B (02616) climbs over 4% in early trade; sales surge after listing in state medical insurance

Stock News
·
Sep 02

CStone Plans First Wave of Global Phase III Trials for Cs2009 by End-2026

Reuters
·
Aug 31

CStone Says Pralsetinib Sales Volume Jumps Nearly 500% After China NRDL Listing

Reuters
·
Aug 31

Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Dow Jones
·
Aug 31

China's Zhaoke Ophthalmology H1 Revenue Rises

Reuters
·
Aug 28

CStone Pharmaceuticals (SEHK:2616) Stock Price Reflects Growth While Losses Stay Heavy

Simply Wall St.
·
Aug 28

New Zealand's Rua Bioscience FY Customer Revenue Jumps on Australia, NZ Growth

Reuters
·
Aug 28

CStone Pharmaceuticals Posts HY Loss of Rmb252.3 Million

Reuters
·
Aug 27

Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Dow Jones
·
Aug 27

China's HBM Holdings H1 Revenue Rises on Progress on Mid-Late Clinical Stage Programs

Reuters
·
Aug 27

Cstone Pharma-B Reports Interim Results with Revenue Surging 314.75% to RMB 205 Million

Stock News
·
Aug 27

China's CStone Pharmaceuticals H1 Revenue Soars on Drug Sales

Reuters
·
Aug 27

CStone Pharmaceuticals - no Dividends Paid, Declared or Proposed During Interim Period

THOMSON REUTERS
·
Aug 27

CStone 1H FY26 Loss Narrows to RMB 252.28 Million; Revenue Rises to RMB 205.1 Million

Reuters
·
Aug 27